Impacts of FDA's Plausible Mechanism Framework for Ultra-Rare Disease Therapies

The FDA has introduced a significant regulatory shift with the release of draft guidance aimed at accelerating the development of individualized therapies for ultra-rare diseases.¹ The Plausible Mechanism Framework provides a structured pathway for obtaining approval for targeted therapies when traditional randomized controlled trials are impractical due to extremely limited patient populations. This initiative, primarily managed by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), addresses the unique challenges of ribonucleic acid (RNA)-based treatments like antisense oligonucleotides and genome-editing technologies. Health and human services Secretary, Robert F. Kennedy, Jr., emphasized in a press release,¹ “President Trump promised to accelerate cures for American families — and we are delivering, especially for children with ultra-rare diseases who cannot afford to wait. We are cutting unnecessary red tape, aligning regulation with modern biology, and clearing a path for breakthrough treatments to reach the patients who need them most.”

What Technical Requirements Define the New Plausible Mechanism Framework?

The draft guidance outlines a shift toward utilizing biological evidence as a cornerstone for effectiveness.¹ To meet the criteria for this framework, sponsors must precisely identify the disease-causing abnormality and demonstrate that their therapy targets the root cause or the proximate biological pathway. Success in pharmaceutical development under this model requires confirming the successful drugging or editing of the target. Furthermore, FDA expects developers to rely on high-quality, well-characterized natural history data from untreated patients to provide a baseline for comparison. Chief medical and scientific Officer and CBER Director Vinay Prasad, MD, MPH, noted the historical significance of this development, stating in a press release,¹ “Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these approvals. The Plausible Mechanism Framework is a revolutionary advance in regulatory science.” For traditional approval under this framework, treatments are still expected to show improved clinical outcomes or changes in biomarkers that are established to predict clinical benefit.

How Will This Framework Impact Manufacturing and Clinical Trial Design?

The shift in regulatory science permits more streamlined approaches to clinical investigations, such as the use of master protocols.¹ This is particularly relevant for manufacturers of technologies that target unique DNA sequences; if a product targets different mutations in a single gene, these variations could be evaluated within a single application. Once a plausible mechanism of action is highly supported, it may serve as the basis for adding further product variants to treat patients with mutations not included in the initial clinical trial. FDA Commissioner Marty Makary, MD, MPH, highlighted this new flexibility, saying,¹ “This guidance is a critical step the FDA is taking to tailor our regulatory approach to patients with ultra-rare conditions. It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases.” While the agency acknowledges the necessity of small sample sizes in these contexts, it requires results to be robust enough to rule out chance findings. CDER acting director Tracy Beth Høeg, MD, Ph.D., explained the broader implications for the industry, in a press release,¹saying, “The Plausible Mechanism draft guidance creates a novel framework through which cutting-edge treatments tailor-made for patients with ultra-rare diseases can be used as a basis for FDA approval. We anticipate our Plausible Mechanism draft guidance will inspire industry to place increased focus on individualized therapies, thereby driving innovation, improving safety, lowering costs and offering more patients with ultra-rare diseases a unique shot at a life-saving treatment.” Professionals in the field have 60 days to submit comments on these proposed guidelines, which may influence future developments in RNA and DNA based therapeutics.

How Else is the FDA Prioritizing Fast Approvals?

To further support the domestic supply chain, FDA has launched the PreCheck pilot program to increase regulatory predictability for manufacturers.² This initiative streamlines facility assessments before specific product applications are submitted, facilitating the construction of sites in the US. Makary, stated in a press release,² “After 35 years of globalists taking pharmaceutical manufacturing overseas, the FDA is taking bold steps to bring it back. The PreCheck program is one of several powerful incentives we are providing to make the U.S. pharmaceutical manufacturing sector more resilient and competitive.”

What Are the Procedural Phases for Participating Manufacturers?

The program utilizes two phases to provide early technical advice and facility-specific drug master files, resolving manufacturing issues before drug application submissions.² This engagement allows FDA to expedite assessments and strengthen the pharmaceutical sector. Selection favors facilities that align with national priorities, such as those producing critical medications for the US market or employing innovative facility development. Participants in the pharmaceutical industry can leverage these phases to enhance the efficiency of their manufacturing assessments.

References

1. U.S. Food and Drug Administration. FDA launches framework for accelerating development of individualized therapies for ultra-rare diseases. FDA. Published 2026. Accessed February 24, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases
2. U.S. Food and Drug Administration. FDA launches PreCheck pilot program to strengthen domestic pharmaceutical manufacturing. FDA. Published 2026. Accessed February 24, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-precheck-pilot-program-strengthen-domestic-pharmaceutical-manufacturing